Determination of MK-287, a new platelet-activating factor antagonist, in plasma and serum by gas chromatography chemical ionization mass spectrometry.
MK-287 is a novel platelet-activating factor antagonist. A sensitive and specific gas chromatographic/mass spectrometric assay has been developed for the determination of the drug in serum and plasma. The assay utilizes an extraction with methyl-t-butyl ether and subsequent trimethylsilylation of the hydroxyl function. The gas chromatographic/mass spectrometric determinations are carried out with temperature-programmed capillary gas chromatography and ammonia negative chemical ionization mass spectrometry. The method has sufficient sensitivity, precision, accuracy and selectivity for the analysis of drug concentrations in clinical samples.
Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
A L
AL
Fisher
M J
MJ
Morris
J D
JD
Gilbert
D005663:Furans / Q000097:blood*; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D066298:In Vitro Techniques; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D010975:Platelet Aggregation Inhibitors / Q000097:blood*; D011863:Radioimmunoassay
D005663:Furans; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; C071469:MK 287